Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances

被引：0

作者：

Thalambedu, Nishanth ^{[1
]}

Lal, Bhavesh Mohan ^{[1
]}

Harbaugh, Brent ^{[2
]}

Alapat, Daisy V. ^{[2
]}

Gaddam, Mamatha ^{[3
]}

Sanchez, Cesar Giancarlo Gentille ^{[3
]}

Kumaran, Muthu ^{[1
]}

Varma, Ankur ^{[3
]}

机构：

[1] Univ Arkansas Med Sci, Dept Hematol & Oncol, Little Rock, AR 72205 USA

[2] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA

[3] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, 4301 W Markham St,Slot 508, Little Rock, AR 72205 USA

来源：

CANCERS | 2025年 / 17卷 / 03期

关键词：

myelodysplastic syndrome; acute myeloid leukemia; pathogenesis; classification; bone marrow dysplasia; HEMATOPOIETIC-CELL TRANSPLANTATION; WORLD-HEALTH-ORGANIZATION; ACUTE MYELOID-LEUKEMIA; LOW-DOSE DECITABINE; SCORING SYSTEM; PROGNOSTIC-FACTORS; OPEN-LABEL; RISK MDS; CLASSIFICATION; SURVIVAL;

D O I：

10.3390/cancers17030508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myelodysplastic syndromes (MDSs), either primary or secondary, are a heterogeneous group of clonal hematological neoplasms characterized by bone marrow dyshematopoiesis, peripheral blood cytopenia, and the potential risk of acute myeloid leukemia (AML) transformation. The clinical heterogeneity in MDS is a reflection of the underlying multitude of genetic defects playing a role in the pathogenesis. Recent advances in the clinicopathological, immunophenotypic, and molecular landscape in understanding the pathophysiology of MDS lead to evolving and refined classification systems with newer entities. Evolving MDS therapies will target the disease's core mechanisms, allowing for personalized treatment based on individual patient's genes and leading to better outcomes. This review provides an overview of MDS pathogenesis to enhance comprehension of its various subgroups. Additionally, we examine the updated classification systems of the World Health Organization (WHO) and the International Consensus Classification (ICC) pertaining to MDS, along with relevant therapeutic approaches.

引用

页数：20

共 50 条

[21] A Call to Arms: Overcoming challenges in Myelodysplastic Syndromes therapy advances
Mcgraw, Kathy L.
Aplan, Peter D.
Pavletic, Steven Z.
SEMINARS IN HEMATOLOGY, 2024, 61 (06) : 345 - 347
[22] Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes
Montalban-Bravo, Guillermo
Garcia-Manero, Guillermo
Jabbour, Elias
CURRENT OPINION IN HEMATOLOGY, 2018, 25 (02) : 146 - 153
[23] From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
Comont, Thibault
Treiner, Emmanuel
Vergez, Francois
DIAGNOSTICS, 2021, 11 (11)
[24] Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes
Ivy, Kathryn S.
Ferrell, P. Brent, Jr.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (04) : 244 - 255
[25] Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
Heise, Carla
Carter, Troy
Schafer, Peter
Chopra, Rajesh
EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1663 - 1672
[26] Primary myelodysplastic syndromes: current views on molecular pathogenetic mechanisms
Klimkovich, NN
Kozareva, TI
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2005, 50 (03): : 41 - 46
[27] The Genetic Basis and Expanding Role of Molecular Analysis in the Diagnosis, Prognosis, and Therapeutic Design for Myelodysplastic Syndromes
Nybakken, Grant E.
Bagg, Adam
JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (02) : 145 - 158
[28] Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions
Navada, Shyamala C.
Silverman, Lewis R.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (01) : 5 - 12
[29] Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions
Shyamala C. Navada
Lewis R. Silverman
Current Hematologic Malignancy Reports, 2011, 6 : 5 - 12
[30] Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?
Chung, Stephen S.
CURRENT OPINION IN HEMATOLOGY, 2016, 23 (02) : 79 - 87

← 1 2 3 4 5 →